Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity
Charlotte Graham, Won‐Ho Lee, Hadley R. Wiggin, Valentina M. Supper, Mark B. Leick, Filippo Birocchi, Andrew J. Yee, Angelina Petrichenko, J.K. Everett, Frederic D. Bushman, Hossein Sadrzadeh, Otto Rapalino, Daniel Chiu, Isabel Arrillaga‐Romany, Marcela V. Maus, Matthew J. Frigault, Kathleen Gallagher
Abstract
In 2 complementary Letters to Blood, Karschnia et al and Graham et al provide new insights into the neurological toxicities that are observed with B-cell maturation antigen–directed chimeric antigen receptor T-cell treatment for multiple myeloma, identifying a frequency of immune effector cell–associated neurotoxicity syndrome (ICANS) that exceeds 40%. Severe ICANS is identified in 8% of patients in this real-world series. Outcomes were generally favorable, although the authors describe rare, late Parkinsonism-like hypokinetic movement disorders (also known as movement and neurocognitive toxicities) post-ICANS in 2 patients.